Cargando…
Phillygenin, a MELK Inhibitor, Inhibits Cell Survival and Epithelial–Mesenchymal Transition in Pancreatic Cancer Cells
INTRODUCTION: Pancreatic cancer (PC) is one of the leading causes of cancer, with the lowest 5-year survival rate of all cancer types. Given the fast metastasis of PC and its resistance to surgery, radiotherapy, chemotherapy, and combinations thereof, it is imperative to develop more effective anti-...
Autores principales: | Li, Hongchun, Chen, Miao, Yang, Zhuying, Wang, Qinxian, Wang, Jiesheng, Jin, Dong, Yang, Xiuyun, Chen, Fuxing, Zhou, Xiumin, Luo, Kexue |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138621/ https://www.ncbi.nlm.nih.gov/pubmed/32308417 http://dx.doi.org/10.2147/OTT.S238958 |
Ejemplares similares
-
Berbamine Suppresses the Growth of Gastric Cancer Cells by Inactivating the BRD4/c-MYC Signaling Pathway
por: Li, Hongchun, et al.
Publicado: (2022) -
Ectopic expression of MELK in oral squamous cell carcinoma and its correlation with epithelial mesenchymal transition
por: Li, Bo, et al.
Publicado: (2021) -
Phillygenin inhibits the inflammation and apoptosis of pulmonary epithelial cells by activating PPARγ signaling via downregulation of MMP8
por: Lin, Yufeng, et al.
Publicado: (2021) -
Evaluation of the Pharmacokinetics and Hepatoprotective Effects of Phillygenin in Mouse
por: Song, Wei, et al.
Publicado: (2018) -
Conversion of epithelial-to-mesenchymal transition to mesenchymal-to-epithelial transition is mediated by oxygen concentration in pancreatic cancer cells
por: Chen, Shuo, et al.
Publicado: (2018)